Table 1.
GWAS studies and their meta-analyses that identified 24 risk loci included in this review.
| Study | Ancestry | Number of cases | |
|---|---|---|---|
| Initial phase (cases vs. controls) | Replication phase (cases vs. controls) | ||
| Nalls et al., 2014# | European Initial phase—*USA, *France, *Germany, *Iceland, *Netherlands, *UK, *23andMe Replication phase—*US, *UK, *France, *Germany, *Greece, *Netherlands, *NeuroX | 13,708 vs. 95,282 | 5,353 vs. 5,551 |
| Vacic et al., 2014 | Ashkenazi Jewish Initial phase—*Israel, *US Replication phase—*Israel, *US | 1,130 vs. 2,611 | 306 vs. 2,583 |
| Hill-Burns et al., 2014 | European Initial phase—*US Replication phase—not reported | 1,565 sporadic cases + 435 familial cases vs. 1,986 controls | 1,528 sporadic cases + 707 familial cases vs. 796 controls |
| Lill et al., 2012# | Initial phase—*US Replication phase—European and Asian | 2,197 vs. 2,061 | Up to 98,080 |
| Pankratz et al., 2012# | European | 4,238 vs. 4,239 | 3,738 vs. 2,111 |
| Do et al., 2011 | European | 3,426 vs. 29,624 | Not applicable |
| Nalls et al., 2011# | Initial phase—*France, *Germany, *UK, *US Replication phase—*US, *France, *Germany, *Netherlands, *Iceland, *UK | 5,333 vs. 12,019 | 7,053 vs. 9,007 |
| Hamza et al., 2010 | European | 2,000 vs. 1,986 | Up to 1,447 vs. 1,468 |
| Saad et al., 2011 | European | 1,039 vs. 1,984 | 3,232 vs. 7,064 |
| Spencer et al., 2011 | Initial phase—*UK Replication phase—*France | 1,705 vs. 5,175 | 1,039 vs. 1,984 |
| Edwards et al., 2010 | European | 1,752 vs. 1,745 | Not applicable |
| Satake et al., 2009 | Japanese | 988 vs. 2,521 | 933 vs. 15,753 |
| Simon-Sanchez et al., 2009 | European | 1,713 vs. 3,978 | 3,361 vs. 4,573 |